Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

413 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial.
Hegde M, Navai S, DeRenzo C, Joseph SK, Sanber K, Wu M, Gad AZ, Janeway KA, Campbell M, Mullikin D, Nawas Z, Robertson C, Mathew PR, Zhang H, Mehta B, Bhat RR, Major A, Shree A, Gerken C, Kalra M, Chakraborty R, Thakkar SG, Dakhova O, Salsman VS, Grilley B, Lapteva N, Gee A, Dotti G, Bao R, Salem AH, Wang T, Brenner MK, Heslop HE, Wels WS, Hicks MJ, Gottschalk S, Ahmed N. Hegde M, et al. Among authors: major a. Nat Cancer. 2024 Jun;5(6):880-894. doi: 10.1038/s43018-024-00749-6. Epub 2024 Apr 24. Nat Cancer. 2024. PMID: 38658775 Clinical Trial.
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.
Lin FY, Stuckert A, Tat C, White M, Ruggieri L, Zhang H, Mehta B, Lapteva N, Mei Z, Major A, Thakkar S, Shum T, Parikh K, Wu MF, Lindsay HB, Scherer L, Shekar M, Baxter P, Wang T, Grilley B, Moeller K, Hicks J, Roy A, Anastas J, Malbari F, Aldave G, Chintagumpala M, Blaney S, Parsons DW, Brenner MK, Heslop HE, Rooney CM, Omer B. Lin FY, et al. Among authors: major a. J Clin Oncol. 2024 Aug 10;42(23):2769-2779. doi: 10.1200/JCO.23.02019. Epub 2024 May 21. J Clin Oncol. 2024. PMID: 38771986 Free PMC article. Clinical Trial.
EWS-FLI1 and RNA helicase A interaction inhibitor YK-4-279 inhibits growth of neuroblastoma.
Sun W, Rojas Y, Wang H, Yu Y, Wang Y, Chen Z, Rajapakshe K, Xu X, Huang W, Agarwal S, Patel RH, Woodfield S, Zhao Y, Jin J, Zhang H, Major A, Hicks MJ, Shohet JM, Vasudevan SA, Coarfa C, Yang J, Nuchtern JG. Sun W, et al. Among authors: major a. Oncotarget. 2017 Oct 19;8(55):94780-94792. doi: 10.18632/oncotarget.21933. eCollection 2017 Nov 7. Oncotarget. 2017. PMID: 29212266 Free PMC article.
Faslpr gene dosage tunes the extent of lymphoproliferation and T cell differentiation in lupus.
Bohat R, Liang X, Chen Y, Xu C, Zheng N, Guerrero A, Hou J, Jaffery R, Egan NA, Li Y, Tang Y, Unsal E, Robles A, Chen S, Major AM, Elldakli H, Chung SH, Liang H, Hicks MJ, Du Y, Lin JS, Chen X, Mohan C, Peng W. Bohat R, et al. Among authors: major am. Clin Immunol. 2024 Jan;258:109874. doi: 10.1016/j.clim.2023.109874. Epub 2023 Dec 17. Clin Immunol. 2024. PMID: 38113962 Free article.
A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma.
Espinoza AF, Patel RH, Patel KR, Badachhape AA, Whitlock R, Srivastava RK, Govindu SR, Duong A, Kona A, Kureti P, Armbruster B, Kats D, Srinivasan RR, Dobrolecki LE, Yu X, Najaf Panah MJ, Zorman B, Sarabia SF, Urbicain M, Major A, Bissig KD, Keller C, Lewis MT, Heczey A, Sumazin P, López-Terrada DH, Woodfield SE, Vasudevan SA. Espinoza AF, et al. Among authors: major a. J Hepatol. 2024 Apr;80(4):610-621. doi: 10.1016/j.jhep.2024.01.003. Epub 2024 Jan 17. J Hepatol. 2024. PMID: 38242326
Maximizing the potential of aggressive mouse tumor models in preclinical drug testing.
Elghetany MT, Ho JM, Shi-Qi LH, Karthik S, Su JMF, Lin Q, Du Y, Shen J, Chow WY, Lau CC, Adesina A, Major A, Erdreich-Epstein A, Hui KM, Li XN, Teo WY. Elghetany MT, et al. Among authors: major a. Sci Rep. 2021 Jun 2;11(1):11580. doi: 10.1038/s41598-021-91167-6. Sci Rep. 2021. PMID: 34079014 Free PMC article.
A second challenge-a major challenge in preclinical drug testing in-vivo among aggressive tumor models, is the narrow therapeutic window to administer drugs within the limited murine lifespan. ...We validated this approach in a second embryonal brain t …
A second challenge-a major challenge in preclinical drug testing in-vivo among aggressive tumor models, is the narrow t …
SOX9 directly regulates IGFBP-4 in the intestinal epithelium.
Shi Z, Chiang CI, Mistretta TA, Major A, Mori-Akiyama Y. Shi Z, et al. Among authors: major a. Am J Physiol Gastrointest Liver Physiol. 2013 Jul 1;305(1):G74-83. doi: 10.1152/ajpgi.00086.2013. Epub 2013 May 9. Am J Physiol Gastrointest Liver Physiol. 2013. PMID: 23660500 Free PMC article.
413 results